NeuroMetrix (Nasdaq: NURO) announced the strategic launch of its Quell Fibromyalgia device through its Pathfinder Program.
The move — announced yesterday — comes nearly 6 months after NeuroMetrix said it had received an FDA de novo authorization to use its Quell neuromodulation device to treat fibromyalgia symptoms.
The Pathfinder Program starts Dec. 1. NeuroMetrix limited the program to 25 key-opinion leaders in fibromyalgia practice across the United States. The key physicians’ guidance will inform NeuroMetrix officials on how to effectively communicate the benefits of Quell to patients and healthcare professionals.
“We are excited to initiate the Pathfinder Program,” said NeuroMetrix CEO Dr. Shai N. Gozani. “By partnering with these physicians, some of the most forward-thinking clinicians on the front lines of fibromyalgia, we will clarify our messaging and distribution process to increase market access and ultimately give patients the best chance of success with our technology.”
NeuroMetrix plans a full Quell Fibromyalgia commercial launch in Q2 2023.
More about NeuroMetrix’s Quell technology
Quell is an advanced, non-invasive neuromodulation device covered by 23 U.S. utility patents. NeuroMetrix describes it as the only wearable neuromodulator with a proprietary microchip to provide precise, high-power nerve stimulation. Also, it’s about the size of a credit card.
Quell utilizes position and motion sensing to adjust stimulation automatically through the day and night. In addition, the device uses Bluetooth low energy (BLE) to communicate with mobile apps in smartphones and smartwatches.